{
    "eid": "2-s2.0-85137294416",
    "title": "Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Immunology and Microbiology (all)",
            "@code": "2400",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Veterinary (all)",
            "@code": "3400",
            "@abbrev": "VETE"
        },
        {
            "@_fa": "true",
            "$": "Public Health, Environmental and Occupational Health",
            "@code": "2739",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Adolescent",
        "Anti-SARS-CoV-2 IgG",
        "BNT162b2 vaccine",
        "Booster dose",
        "CoronaVac vaccine",
        "Neutralizing antibody titer",
        "SARS-CoV-2 vaccine"
    ],
    "authors": [
        "Thanyawee Puthanakit",
        "Rapisa Nantanee",
        "Peera Jaru-Ampornpan",
        "Napaporn Chantasrisawad",
        "Jiratchaya Sophonphan",
        "Thutsanun Meepuksom",
        "Thidarat Jupimai",
        "Pimpayao Sodsai",
        "Suvaporn Anugulruengkitt",
        "Nattiya Hirankarn"
    ],
    "citedby-count": 1,
    "ref-count": 36,
    "ref-list": [
        "SARS-CoV-2 vaccines in development",
        "Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents",
        "Anti-SARS-CoV-2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID-19 vaccination regimens",
        "Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers",
        "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",
        "Expert consensus on COVID-19 vaccination in children",
        "Vaccination of children against COVID-19: the experience in Latin America",
        "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5\u201311 Years - United States, November 2021",
        "Plasma Neutralization of the SARS-CoV-2 Omicron Variant",
        "Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant",
        "Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022",
        "A serological assay to detect SARS-CoV-2 seroconversion in humans",
        "A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines",
        "Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac",
        "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction",
        "Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection",
        "Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England",
        "Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario",
        "The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged >/=18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022",
        "Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5\u201317 Years - VISION Network, 10 States, April 2021-January 2022",
        "Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022",
        "The T cell immune response against SARS-CoV-2",
        "Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccine",
        "Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence for Pediatric Infectious Diseases and Vaccines",
        "Department of Diseases Control",
        "HIV Netherlands Australia Thailand Research Collaboration",
        "Monoclonal Antibody Production and Application Research Team",
        "National Vaccine Institute, Thailand",
        "Department of Pediatrics",
        "Chulalongkorn University",
        "Ministry of Public Health, Thailand",
        "Faculty of Medicine, Chulalongkorn University",
        "BIOTEC",
        "Department of Microbiology, Faculty of Medicine, Chulalongkorn University"
    ]
}